23.09.2014 - Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.
The target size of the Aglaia Oncology Fund II is US$80m to US$100m. Like its predecessor Aglaia Oncology Fund I, the new fund is backed by high-net-worth families, but they have now been joined by several institutional investors, including the European Investment Fund (EIF). It is also one of the funds selected under the Dutch Venture Initiative – an investment fund recently launched by the Netherlands Ministry of Economic Affairs.
The Bilthoven-based venture capitalist wants to invest the money in ten to fifteen biotech startups with a focus on developing technologies for the treatment and prevention of cancer. “We demonstrated the effectiveness of our strategy with our first fund. The confidence our investors have placed in us will now enable us to use this new fund to substantially increase our contribution in the fight against cancer by building a portfolio of companies engaged in developing truly innovative anti-cancer medications,” commented Aglaia Partner Mark Krul.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.